PL436747A1 - Use of a 1,3-benzodioxole-5-sulfonyl quinazoline derivative in the manufacture of a drug with antineoplastic activity - Google Patents

Use of a 1,3-benzodioxole-5-sulfonyl quinazoline derivative in the manufacture of a drug with antineoplastic activity

Info

Publication number
PL436747A1
PL436747A1 PL436747A PL43674721A PL436747A1 PL 436747 A1 PL436747 A1 PL 436747A1 PL 436747 A PL436747 A PL 436747A PL 43674721 A PL43674721 A PL 43674721A PL 436747 A1 PL436747 A1 PL 436747A1
Authority
PL
Poland
Prior art keywords
benzodioxole
sulfonyl
drug
manufacture
quinazoline derivative
Prior art date
Application number
PL436747A
Other languages
Polish (pl)
Other versions
PL242765B1 (en
Inventor
Robert Musioł
Jacek Mularski
Katarzyna Malarz
Original Assignee
Uniwersytet Śląski W Katowicach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Śląski W Katowicach filed Critical Uniwersytet Śląski W Katowicach
Priority to PL436747A priority Critical patent/PL242765B1/en
Publication of PL436747A1 publication Critical patent/PL436747A1/en
Publication of PL242765B1 publication Critical patent/PL242765B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie 1,3-benzodioksolo-5-sulfonylowej pochodnej chinazoliny przedstawionej wzorem 1 do wytwarzania leku o działaniu przeciwnowotworowym, zwłaszcza wobec białaczek, nowotworów jelit lub mózgu.The present invention relates to the use of a 1,3-benzodioxole-5-sulfonyl quinazoline derivative represented by the formula I for the preparation of a medicament with antitumor activity, especially against leukemias, intestinal or brain tumors.

PL436747A 2021-01-25 2021-01-25 1,3-benzodioxole-5-sulfonyl quinazoline derivative for use in the treatment of cancer PL242765B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL436747A PL242765B1 (en) 2021-01-25 2021-01-25 1,3-benzodioxole-5-sulfonyl quinazoline derivative for use in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL436747A PL242765B1 (en) 2021-01-25 2021-01-25 1,3-benzodioxole-5-sulfonyl quinazoline derivative for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
PL436747A1 true PL436747A1 (en) 2022-08-01
PL242765B1 PL242765B1 (en) 2023-04-17

Family

ID=83721734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL436747A PL242765B1 (en) 2021-01-25 2021-01-25 1,3-benzodioxole-5-sulfonyl quinazoline derivative for use in the treatment of cancer

Country Status (1)

Country Link
PL (1) PL242765B1 (en)

Also Published As

Publication number Publication date
PL242765B1 (en) 2023-04-17

Similar Documents

Publication Publication Date Title
ZA202300924B (en) Quinoxaline derivatives as anti-cancer drugs
CY1123353T1 (en) NOVEL CONDUCTED PYRIMIDINE COMPOUND OR SALT THEREOF
GEAP202215535A (en) Compounds
CL2024000067A1 (en) Antiviral compounds
GEAP202215475A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
DOP2021000017A (en) PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO PREVENT OR TREAT CANCERS INCLUDING THE SAME
PH12018500437B1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
CR10056A (en) [(1H-INDOL-5-IL) -HETEROARILOXI] - (1-AZA-BICICLO [3.3.1] NONANS AS N-ACHR COLLINERIC LIGANDS FOR THE TREATMENT OF PISCOTIC AND NEURODEGENERATIVE DISORDERS
MX2022004451A (en) HETEROARYL-BIPHENYL-AMIDES FOR THE TREATMENT OF DISEASES RELATED TO THE PD-L1 LIGAND.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
GEP20196954B (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
NI201000145A (en) DERIVATIVES OF IMIDAZINE - [1, 2-b] - PYRIDAZINE FOR THE TREATMENT OF DISEASE MEDIATED BY TYROSINE KINASE C-MET.
BR112019006047A2 (en) compounds, one or two or more compounds, pharmaceutically acceptable salt, methanesulfonate salt, ret kinase inhibitor, medicament, uses of the compound and a compound, methods for treating or preventing cancer and for treating or preventing cancer in an individual, and, composition pharmaceutical
ECSP099322A (en) CHEMICAL COMPOUNDS
CY1111203T1 (en) 4-ANILINOKINOLINO-3-CARBOXAMIDE AS MOVEMENT INHIBITORS CSF-1R
SA519402180B1 (en) Novel Heterocyclic Compound, its Preparation Method, and Pharmaceutical Composition Comprising The Same
PH12021500034A1 (en) Compounds useful in hiv therapy
MD20160016A2 (en) New indolizine compounds, process for making them and pharmaceutical compositions containing them
MX390835B (en) HIGH SURFACE AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS
BR112022009805A2 (en) PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS
CL2021002480A1 (en) Macrocyclic compound agonists such as Sting's
EA201490630A1 (en) 6-SUBSTITUTED 3- (QUINOLIN-6-ILTIO) [1,2,4] TRIAZOLO [4,3-A] Pyridine as inhibitors of C-MET THYROZINKINASE
MX2025002790A (en) 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
MX2023014131A (en) 7-nitro-8-hydroxyquinoline derivative, preparation method therefor and medical use thereof.
EA202092361A1 (en) CONJUGATE OF A CYTOTOXIC DRUG AND PRODrug FORM OF THE SPECIFIED CONJUGATE